Q1 2024 Earnings Estimate for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Issued By HC Wainwright

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Nuvectis Pharma in a report issued on Monday, April 8th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.39) per share for the quarter. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.38) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.22) EPS and FY2028 earnings at ($2.66) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last posted its earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01).

Nuvectis Pharma Price Performance

Nuvectis Pharma stock opened at $7.02 on Thursday. The firm has a market capitalization of $124.75 million, a price-to-earnings ratio of -4.91 and a beta of 0.28. The company’s 50 day simple moving average is $8.48 and its 200 day simple moving average is $8.76. Nuvectis Pharma has a fifty-two week low of $6.20 and a fifty-two week high of $18.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVCT. Citigroup Inc. bought a new position in shares of Nuvectis Pharma during the 2nd quarter valued at about $33,000. California State Teachers Retirement System bought a new position in Nuvectis Pharma in the second quarter valued at approximately $36,000. Royal Bank of Canada acquired a new position in shares of Nuvectis Pharma in the second quarter valued at approximately $43,000. Wells Fargo & Company MN increased its position in shares of Nuvectis Pharma by 11,280.0% during the second quarter. Wells Fargo & Company MN now owns 2,845 shares of the company’s stock worth $45,000 after acquiring an additional 2,820 shares in the last quarter. Finally, Strs Ohio raised its holdings in shares of Nuvectis Pharma by 178.6% during the third quarter. Strs Ohio now owns 3,900 shares of the company’s stock worth $50,000 after acquiring an additional 2,500 shares during the period. 96.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Nuvectis Pharma

In other news, CEO Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock in a transaction dated Monday, March 18th. The shares were bought at an average cost of $10.29 per share, with a total value of $51,450.00. Following the completion of the transaction, the chief executive officer now directly owns 3,242,484 shares in the company, valued at approximately $33,365,160.36. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 38.85% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.